Following my Written Question E-003237/2017 regarding the clawback of the Greek pharmaceutical sector, a provision for a 30% clawback reduction for 2017 vs 2016 and 15% for 2018 vs 2017 was included in the supplementary memorandum of understanding of the third bailout agreement between Greece and its creditors. It is worth mentioning that pharmaceutical companies in Greece account for 27.3% of total pharmaceutical expenditure, while the average pharma contribution in the EU is 8.6% and the second highest contribution is from Germany at 13.3%. The introduction of a new rebate scheme with an extra 25% (effective retroactively since 1 January 2017) mandatory entrance fee for new drugs also failed to reduce the 2017 clawback. For 2017 the projected contribution of the Greek pharmaceutical industry will reach some EUR 1 billion.

Has the target of a 30% clawback reduction for 2017 vs 2016 been achieved?

If not, and since the 30% reduction was a prerequisite, are the supervising institutions willing to address this matter with the Greek Ministry of Health?

The environment has become highly unsustainable. How will patient access to innovation be affected if companies decide to no longer launch their products in Greece?